A. Scheliga
AuthID: R-00F-FF3
1
TÃTULO: AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
AUTORES: Leonard, JP; Trneny, M; Izutsu, K; Fowler, NH; Hong, X; Zhu, J; Zhang, H; Offner, F; Scheliga, A; Nowakowski, GS; Pinto, A; Re, F; Fogliatto, LM; Scheinberg, P; Flinn, IW; Moreira, C; Cabeçadas, J; Liu, D; Kalambakas, S; Fustier, P; ...Mais
PUBLICAÇÃO: 2019, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 37, NÚMERO: 14
AUTORES: Leonard, JP; Trneny, M; Izutsu, K; Fowler, NH; Hong, X; Zhu, J; Zhang, H; Offner, F; Scheliga, A; Nowakowski, GS; Pinto, A; Re, F; Fogliatto, LM; Scheinberg, P; Flinn, IW; Moreira, C; Cabeçadas, J; Liu, D; Kalambakas, S; Fustier, P; ...Mais
PUBLICAÇÃO: 2019, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 37, NÚMERO: 14
INDEXADO EM: 
Scopus 
WOS
Scopus WOS2
TÃTULO: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
AUTORES: Bertrand Coiffier; Weimin M Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko Jarosinska; Sven de Vos; ...Mais
PUBLICAÇÃO: 2013, FONTE: CLINICAL CANCER RESEARCH, VOLUME: 19, NÚMERO: 9
AUTORES: Bertrand Coiffier; Weimin M Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko Jarosinska; Sven de Vos; ...Mais
PUBLICAÇÃO: 2013, FONTE: CLINICAL CANCER RESEARCH, VOLUME: 19, NÚMERO: 9
3
TÃTULO: EFFICACY AND SAFETY OF BORTEZOMIB-RITUXIMAB (VCR) VS RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED, R-NAIVE/-SENSITIVE FOLLICULAR LYMPHOMA (FL): OUTCOME ACCORDING TO PRIOR THERAPY
AUTORES: Crump, M; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, DL; Enny, C; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLICAÇÃO: 2011, FONTE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
AUTORES: Crump, M; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, DL; Enny, C; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLICAÇÃO: 2011, FONTE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
INDEXADO EM: WOS
WOS4
TÃTULO: TIME TO NEXT ANTI-LYMPHOMA THERAPY (TTNT) AND TREATMENT-FREE INTERVAL (TFI) WITH BORTEZOMIB-RITUXIMAB (VCR) VS RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL)
AUTORES: Kimby, E; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, D; Theocharous, P; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLICAÇÃO: 2011, FONTE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
AUTORES: Kimby, E; Scheliga, A; Mayer, J; Offner, F; Teixeira, A; Kuliczkowski, K; Liberati, AM; Okada, CY; Esseltine, D; Theocharous, P; Zhu, E; Van de Velde, H; Elsayed, YA; Coiffier, B;
PUBLICAÇÃO: 2011, FONTE: 11th International Conference on Malignant Lymphoma in ANNALS OF ONCOLOGY, VOLUME: 22
INDEXADO EM: WOS
WOS